Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6JYUO)

Drug Name
Tinlarebant Drug Info
Synonyms
Tinlarebant; Tinlarebant [USAN]; LBS-008; BPN-14967; 63WI9S8P1M; UNII-63WI9S8P1M; WHO 11058; 1-(3-(4-(3,4-Difluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo(3,4-C)pyridin-6-yl)ethan-1-one; 1821327-95-0; Ethanone, 1-(3-((4-(3,4-difluoro-2-(trifluoromethyl)phenyl)-1-piperidinyl)carbonyl)-1,4,5,7-tetrahydro-6H-pyrazolo(3,4-C)pyridin-6-yl); TINLAREBANT [INN]; CHEMBL3967849; SCHEMBL17223028; BDBM249482; US9434727, 80; US9434727, 81; 1-(3-(4-(3,4-difluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-4,5-dihydro-1H-pyrazolo[3,4-c]pyridin-6(7H)-yl)ethanone
Indication
Disease Entry ICD 11 Status REF
Stargardt disease 9B70 Phase 3 [1]
Cross-matching ID
PubChem CID
92044505
TTD Drug ID
DM6JYUO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasma retinol-binding protein (RBP4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
A1-10436 DM9ESPR N. A. N. A. Patented [3]
US9434727, 93 DMCJG8Z N. A. N. A. Patented [4]
US9434727, 153 DMC812I N. A. N. A. Patented [5]
US9434727, 40 DMLPWK3 N. A. N. A. Patented [6]
US8586571, 12 DMKLJ6O N. A. N. A. Patented [7]
A1-10438 DMJD1S6 N. A. N. A. Patented [3]
US8586571, 36 DMX3A0O N. A. N. A. Patented [7]
US8853215, 3 DMX8NLB N. A. N. A. Patented [3]
US8586571, 6 DM1N74R N. A. N. A. Patented [7]
US9434727, 120 DMIT0H3 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasma retinol-binding protein (RBP4) TT0C8BY RET4_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT05244304) Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects. U.S.National Institutes of Health.
2 Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. Eur J Med Chem. 2021 Dec 15;226:113856.
3 Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215.
4 Substituted 4-phenylpiperidines, their preparation and use. US10072016.
5 Substituted 4-phenylpiperidines, their preparation and use. US9434727.
6 Substituted 4-phenylpiperidines, their preparation and use. US9777010.
7 Heterocyclic compound. US8586571.